Biocon Brings GLP-1 Therapy for Diabetes, Obesity to Netherlands

The therapeutics market in diabetes and obesity treatment in Europe is exhibiting a consistent growth due to the increasing incidence of metabolic diseases, escalating interest in GLP-1 drug therapy and the increasing interest in biologics that are affordable. It is against this background that Biocon has announced that it has launched its GLP-1 peptide, Liraglutide, in the Netherlands, which is one of the strategic moves in its European growth.

Liraglutide for diabetes (gVictoza) and obesity (gSaxenda) will be introduced by Biocon under the distribution of Pharmamedic B.V. in the local market. The combination of the drug and the device will be promoted as Diavorin to treat diabetes and Vobexoryn to treat chronic weight. This is after the Medicines Evaluation Board (MEB), Netherlands, gave it regulatory approval earlier this year.

It is noteworthy that the Netherlands will be the first EU nation where Biocon is launching Liraglutide as a brand of its own directly, which will further solidify its footprint in the environment of the extremely competitive GLP-1 and metabolic illness treatment environment. The opening highlights the importance of peptide-based therapeutics to the Biocon Company and its desire to expand accessibility of affordable diabetes and obesity care in controlled international markets.

Commenting on the milestone, Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon, said: “The launch of Liraglutide in the Netherlands marks a significant milestone in expanding Biocon's GLP-1 portfolio across key global markets, and reinforces the strategic importance of peptide-based therapies within our portfolio.”

Biocon is a multinational pharmaceutical firm dealing with biopharmaceuticals, which aims at enhancing low cost access to chronic disease treatments, such as diabetes, cancer, and autoimmune illnesses, by means of creativity, magnitude, and combined manufacturing capacities.